| Schedule of Earnings Per Share Basic and Diluted |
Schedule
of Earnings Per Share Basic and Diluted
| | |
March 31, 2026 | | |
March 31, 2025 | |
| | |
Three Months Ended | |
| | |
March 31, 2026 | | |
March 31, 2025 | |
| Numerator: | |
(in thousands, except per share data) | |
| Net loss attributable to common stockholders | |
$ | (6,703 | ) | |
$ | (2,162 | ) |
| Less: preferred dividends | |
| (221 | ) | |
| — | |
| Net loss attributable to common shareholders | |
| (6,924 | ) | |
| (2,162 | ) |
| Denominator: | |
| | | |
| | |
| Weighted-average common shares outstanding | |
| 16,989 | | |
| 2,964 | |
| | |
| | | |
| | |
| Net loss per common share | |
$ | (0.41 | ) | |
$ | (0.73 | ) |
|
Schedule
of Earnings Per Share Basic and Diluted
| | |
2025 | | |
2024 | |
| | |
Years Ended December 31, | |
| | |
2025 | | |
2024 | |
| Numerator: | |
| (in thousands, except per share data) | |
| Net loss attributable to common stockholders | |
$ | (10,549 | ) | |
$ | (11,017 | ) |
| Less: preferred dividends | |
| (533 | ) | |
| — | |
| Net loss attributable to common shareholders | |
| (11,082 | ) | |
| (11,017 | ) |
| Denominator: | |
| | | |
| | |
| Weighted-average common shares outstanding | |
| 4,969 | | |
| 2,938 | |
| | |
| | | |
| | |
| Net loss per common share | |
$ | (2.23 | ) | |
$ | (3.75 | ) |
|
| Schedule of Antidilutive Securities Earnings Per Share |
The
following potential common share equivalents were excluded from the calculation of diluted net income per share because their effect
would have been anti-dilutive in the period presented (in thousands):
Schedule
of Antidilutive Securities Earnings Per Share
| | |
March 31, | | |
December 31, | |
| | |
2026 | | |
2025 | |
| Convertible preferred stock | |
| 15,514 | | |
| 20,782 | |
| Common Stock Warrants | |
| 25,376 | | |
| 26,421 | |
| Preferred Stock Warrants | |
| 247 | | |
| 247 | |
| Stock options | |
| 14,903 | | |
| 7,337 | |
| Total potential common stock excluded from net loss per share | |
| 56,040 | | |
| 54,787 | |
|
The
following potential common share equivalents were excluded from the calculation of diluted net income per share in FY 2025 because their
effect would have been anti-dilutive in the period presented (in thousands):
Schedule
of Antidilutive Securities Earnings Per Share
| | |
2025 | | |
2024 | |
| | |
Years Ended December 31, | |
| | |
2025 | | |
2024 | |
| Convertible preferred stock | |
| 20,782 | | |
| 26,560 | |
| Common Stock Warrants | |
| 26,421 | | |
| — | |
| Preferred Stock Warrants | |
| 247 | | |
| 247 | |
| Stock options | |
| 7,337 | | |
| 5,027 | |
| Total potential common stock excluded from net loss per share | |
| 54,787 | | |
| 31,834 | |
|